Antitumor Virotherapy by Attenuated Measles Virus (MV).
Antitumor virotherapy consists of the use of replication-competent viruses to infect and kill tumor cells preferentially, without damaging healthy cells. Vaccine-attenuated strains of measles virus (MV) are good candidates for this approach. Attenuated MV uses the CD46 molecule as a major entry receptor into cells. This molecule negatively regulates the complement system and is frequently overexpressed by cancer cells to escape lysis by the complement system. MV exhibits oncolytic properties in many cancer types in vitro, and in mouse models. Phase I clinical trials using MV are currently underway. Here, we review the state of this therapeutic approach, with a focus on the effects of MV on the antitumor immune response.
INSERM, UMR892, Nantes, F-44000, France. jean-baptiste.guillerme@univ-nantes.fr.
Jean-Baptiste
JB
Guillerme
INSERM, UMR892, Nantes, F-44000, France. marc.gregoire@nantes.inserm.fr.
Marc
M
Gregoire
CNRS, URA3015, Institut Pasteur, Unité de Génomique Virale et Vaccination, Paris, 75015, France. ftangy@pasteur.fr.
Frédéric
F
Tangy
INSERM, UMR892, Nantes, F-44000, France. jean-francois.fonteneau@inserm.fr.
Jean-François
JF
Fonteneau